Abbvie Inc

NYSE: ABBV
$175.17
-$3.33 (-1.9%)
Closing Price on January 10, 2025

ABBV Articles

The January 13 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mostly down.
The health care sector has some of its biggest players reporting later this week, with one pharma giant’s report already out of the way.
A new Jefferies research report makes the case that while market parameters are indeed expensive, there still are cheap stocks to buy that have a large enough market cap to provide some safety.
24/7 Wall St. has put together a preview of AT&T, AbbVie, Starbucks and some of the major companies scheduled to share their quarterly results in the coming days.
The short interest data have been released for the December 30 settlement date. Pharmaceutical companies usually are involved in a lengthy process in getting their drug candidates to market through...
The December 15 short interest data have been compared with the previous figures, and short interest increased in most of these selected pharmaceutical stocks.
A top new addition to the Franchise list portfolio and three additional dividend stocks that the Jefferies team views as their top high conviction picks.
The November 30 short interest data have been compared with the previous figures, and short interest decreased in these selected pharmaceutical stocks.
With money expected to come out of the bond market, these four stocks are an attractive alternative that have solid upside potential, and they are the highest conviction picks at Jefferies.
The November 15 short interest data have been compared with the previous figures, and short interest was mixed in the selected pharmaceutical stocks.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. With earnings for the third quarter over, and the fourth...
Drug prices have been under pressure due to the campaign rhetoric, and short interest has increased in most of these selected pharmaceutical stocks.
In a recent research note, the analysts at Jefferies make a big move by removing a top medical devices company from the firm's well-respected Franchise Picks list of stocks.
The relentless populist rhetoric has lowered the prices on some of the top pharmaceutical companies, and long-term growth and income investors have a chance to buy some great stocks on sale.
The top analyst upgrades, downgrades and initiations seen on Monday morning include AbbVie, Chevron, Home Depot, Nike, Qualcomm and VMware.
AI Portfolio

Discover Our Top AI Stocks

Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.

You can follow him investing $500,000 of his own money on our top AI stocks for free.